SLC5A2 and prostate carcinoma: Studies have found that SGLT2 is functionally expressed in prostate cancer and that canagliflozin inhibits mitochondrial complex I-supported respiration and cell proliferation in prostate cancer cells to reduce cancer cell proliferation and enhance their sensitivity to radiotherapy (36, 46, 47), providing a basis for the use of SGLT2i in prostate cancer.